Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma
DRUG: Anlotinib+ Liposomal Doxorubicin
Progress free survival (PFS), Calculated from the date of treatment start until last follow-up or death, whichever comes first., each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)
Overall Survival (OS), Calculated from the date of treatment start until last follow-up or death, whichever comes first., From randomization until death (up to 24 months)|Objective Response Rate (ORR), Overall objective response measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), Disease Control Rate measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)|Quality of Life (QoL), QoL is measured by the World Health Organization Quality of Life (WHOQOL-BREF), each 42 days to evaluate up to intolerance the toxicity or PD (in first 24 weeks), each 84 days to evaluate up to intolerance the toxicity or PD (up to 24 months)
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma